Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase

Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase

Background: HY-021068 [4-(2-(1H-imidazol-1-yl) ethoxy)-3-methoxybenzoate], developed by Hefei Industrial Pharmaceutical Institute Co., Ltd. (Anhui, China), is a potential thromboxane synthetase inhibitor under development as an anti-platelet agent for the treatment of stroke. A semi-mechanistic phar...

Full description

Bibliographic Details
Main Authors: Ping Li, Jie Huang, Donghao Geng, Peihua Liu, Zhaoxing Chu, Jianjun Zou, Guoping Yang, Li Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Pharmacology
Subjects:
pharmacokinetic/pharmacodynamic model
platelet aggregation rate
HY-021068
pharmacokinetic
thromboxane A2
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.588286/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.588286/full

Similar Items